Pesticides use in vegetable production often has residual effects on the plants and environment with potential health risks. Diazinon, though associated with human health impacts, is a popular pesticide in the production of Brassica oleracea var. acephala at the Kimira-Oluch Smallholder Farmers Improvement Project (KOSFIP), Kenya. The long preharvest interval (PHI) of diazinon application may not be observed by farmers with inadequate appreciation of Good Agricultural Practices (GAP). It is not documented whether diazinon residues levels in the farm-gate Brassica oleracea var. acephala of KOSFIP could be a health risk to the consumers. The diazinon residues levels and corresponding health risks in farm-gate Brassica oleracea var, acephala at KOSFIP were determined. Cross-sectional survey based on snowball sampling identified 40 farms applying diazinon on the vegetable. Triplicate samples were collected from each farm for residue analysis, using the QuEChERS method, and LC-ESI-MS/MS analysis. Standard normal distribution function f(z), revealed ≈ 78% of farm-gate samples had detectable residual diazinon levels and 70% were above the Codex MRL of 0.05 mg/kg. The farm-gate Brassica oleracea var. acephala are exposing consumers to health risks. Efforts must be intensified to ensure GAP are adopted. The estimated farm-gate samples with health risk indices for children and adults (HRIc and HRIA) >1.0 were 64% and 26%, respectively. Farm-gate Brassica oleracea var. acephala diazinon levels are therefore causing high health risks to both children and adults. Farm-gate residual levels and HRI were comparatively higher than findings of most previous studies. Inappropriate label PHI and malpractices against GAP may be responsible for high residual levels. There should be regular surveillance and trainings of farmers on GAP for sustainable production of Brassica oleracea var. acephala in the Lake Victoria region. Use of diazinon on Brassica oleracea var. acephala should be discouraged and alternative approaches including integrated pest management practices should be encouraged.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The design did not require ethical approval

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present work are contained in the manuscript